Although the genomics for our study were descriptive in nature and objective responses were infrequent, outcomes appeared worse for patients with co-occurring inactivating alterations in cell-cycle regulators TP53 and CDKN2A. A recent, large retrospective study reported that TP53 and CDK2NA alterations have prognostic implications in cholangiocarcinoma, with worse outcomes after adjusting for stage and other known prognostic factors26. This evidence concerns the gene TP53 and cholangiocarcinoma.